Progranulin Therapy

📖 Wiki Page

therapeutic1583 wordssynced 2026-04-02

Progranulin Therapy

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Progranulin Therapy</th>
</tr>
<tr>
<td class="label">Trial ID</td>
<td>Therapy</td>
</tr>
<tr>
<td class="label">NCT04885114</td>
<td>PBFT02 (gene therapy)</td>
</tr>
<tr>
<td class="label">NCT06064890</td>
<td>AVB-101 (gene therapy)</td>
</tr>
<tr>
<td class="label">NCT05549648</td>
<td>LY3884963 (small molecule)</td>
</tr>
<tr>
<td class="label">NCT05864330</td>
<td>VES001 (small molecule)</td>
</tr>
<tr>
<td class="label">NCT05725190</td>
<td>DNL593 (protein therapy)</td>
</tr>
</table>

Progranulin therapy refers to therapeutic strategies designed to restore progranulin (PGRN) levels in the central nervous system to treat frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions associated with progranulin deficiency.[@baker2006][@cruts2006] Progranulin is a secreted glycoprotein encoded by the [GRN gene](/genes/grn) that plays critical roles in neuronal survival, lysosomal function, synaptic plasticity, and inflammation modulation.[@kelley2020]

...

Progranulin Therapy

Overview

Loss-of-function mutations in [GRN](/genes/grn) cause haploinsufficiency, resulting in approximately 50% reduction in progranulin levels, which leads to frontotemporal dementia (FTD-GRN) characterized by TDP-43 proteinopathy.[@ward2007][@ghidoni2008] Therapeutic approaches aim to boost progranulin expression or deliver functional progranulin protein to prevent or slow neurodegeneration.

Mechanism of Action

Progranulin Deficiency in Disease

GRN mutations causing FTD are typically null alleles that result in haploinsufficiency:

Mechanism: ~50% reduction in progranulin protein levels
Pathology: TDP-43 positive inclusions (type A) throughout the brain
Clinical phenotypes: Behavioral variant FTD, primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy
Age of onset: Typically 45-65 years, with high penetrance

Progranulin deficiency leads to:

Lysosomal dysfunction: Impaired lysosomal biogenesis and function
Increased neuroinflammation: Enhanced microglial activation
TDP-43 mislocalization: Cytoplasmic TDP-43 inclusions
Neuronal vulnerability: Reduced neurotrophic support
Impaired [autophagy](/entities/autophagy): Disrupted protein clearance pathways

Therapeutic Target

Progranulin therapy aims to:

Restore physiological progranulin levels to above the therapeutic threshold

Improve lysosomal function in [neurons](/entities/neurons) and [microglia](/cell-types/microglia-neuroinflammation)

Reduce neuroinflammation through immunomodulatory effects

Protect against TDP-43 pathology

Support neuronal survival through neurotrophic activity

Therapeutic Strategies

1. Gene Therapy (AAV-Mediated)

Recombinant adeno-associated virus (AAV) delivery of the GRN gene offers sustained progranulin expression:

PBFT02: AAV-based gene therapy delivering GRN to the CNS; currently in Phase 1b for FTD-GRN patients[@pbft]
AVB-101: AAV gene therapy targeting bilateral intrathalamic infusion; in Phase 1/2 trials for FTD-GRN[@avb]
Vector optimization: Use of neuronal-specific promoters (Synapsin, CamKII) for targeted expression
Delivery methods: Intracerebral, intracisterna magna (ICM), or intrathalamic administration

Advantages: Long-lasting expression, single-dose potential Challenges: Invasive delivery, immune response to viral vectors, achieving adequate brain distribution

2. Protein Replacement Therapy

Direct delivery of recombinant progranulin protein:

FRM-0334: Recombinant progranulin protein; studied in Phase 1/2 trials for FTD-GRN[@frm]
DNL593: Engineered progranulin variant with enhanced CNS penetration; in clinical development[@dnl]

Advantages: Direct protein delivery, measurable pharmacodynamics Challenges: [Blood-brain barrier](/entities/blood-brain-barrier) penetration, short half-life, repeated dosing requirements

3. Small Molecule Progranulin Boosters

Oral pharmacological approaches to increase endogenous progranulin:

LY3884963: Small molecule progranulin enhancer; in Phase 1/2 trials for FTD-GRN[@clinical]
VES001: Oral progranulin-boosting compound; in multiple clinical trials for asymptomatic and symptomatic GRN carriers[@ves]
Mechanism: Upregulation of GRN gene expression through transcriptional activation
Alternative targets: Inhibition of progranulin degradation pathways

Advantages: Oral bioavailability, non-invasive delivery Challenges: Achieving adequate CNS exposure, mechanism validation

4. Antisense Oligonucleotides (ASOs)

ASO-based approaches to modulate GRN expression:

Target: Increase GRN mRNA translation or reduce degradation
Delivery: Intrathecal administration to reach CNS
Status: Preclinical development stage

5. Cell-Based Therapy

Cell platforms for progranulin delivery:

Engineered mesenchymal stem cells (MSCs): Modified to secrete progranulin
Encapsulated cell biodelivery (ECB): Implantable devices with engineered cells
Status: Preclinical/early translational stage

Clinical Development Status

Active Clinical Trials

Clinical Trial Summary

Gene Therapy Trials:

PBFT02: Phase 1b open-label, multicenter study assessing safety and pharmacodynamic effects of PBFT02 delivered into the cisterna magna in adults with FTD and GRN or [C9ORF72](/entities/c9orf72) mutations[@pbft]
AVB-101: Phase 1/2 study evaluating safety and preliminary efficacy administered by bilateral intrathalamic infusion in subjects with FTD-GRN[@avb]

Small Molecule Trials:

LY3884963: Phase 1/2 ascending dose study to evaluate safety and effects on progranulin levels in FTD-GRN patients[@clinical]
VES001: Multiple studies including asymptomatic GRN mutation carriers and symptomatic FTD-GRN patients[@ves]

Protein Therapy Trials:

DNL593: Study to evaluate safety, tolerability, PK, and PD in healthy participants and FTD-GRN patients[@dnl]
FRM-0334: Completed Phase 1 study evaluating plasma progranulin changes[@frm]

Biomarkers for Clinical Trials

Progranulin Level Monitoring

Plasma progranulin: Primary pharmacodynamic biomarker
CSF progranulin: CNS exposure indicator
Emerging: CSF/serum [neurofilament light](/biomarkers/neurofilament-light-chain-nfl) chain (NfL) as neurodegenerative marker

Disease Progression Markers

Neurofilament light chain (NfL): Marker of neuronal injury
Neuroimaging: MRI volumetric measures of brain atrophy
Cognitive assessments: CDR, FBI, CAMCOG for FTD

Trial Design Considerations

Pre-symptomatic carriers: Prevention trials in asymptomatic GRN mutation carriers
Biomarker-driven enrollment: Use of progranulin levels and NfL for patient selection
Combination endpoints: Clinical and biomarker outcomes

Preclinical Evidence

Animal Models

Grn knockout mice: Show increased neuroinflammation, lysosomal abnormalities, and age-dependent neurodegeneration
AAV-Grn delivery: Rescues behavioral deficits and neuropathology in Grn-deficient mice
Protein delivery: Recombinant progranulin improves lysosomal function in models

Key Preclinical Findings

Progranulin overexpression protects against excitotoxicity and oxidative stress

AAV-mediated GRN delivery restores progranulin levels and improves survival in animal models

Small molecule GRN enhancers increase progranulin expression in vitro and in vivo

Combination approaches (gene therapy + small molecules) show synergistic effects

Therapeutic Applications

Frontotemporal Dementia (FTD-GRN)

Primary indication for progranulin therapy:

Targets the underlying genetic cause
Aims to prevent or slow TDP-43 pathology
May be most effective in pre-symptomatic carriers

Amyotrophic Lateral Sclerosis (ALS)

GRN mutations can co-occur with ALS:

Overlapping TDP-43 pathology
Progranulin therapy may benefit ALS patients with GRN mutations
Clinical trials include FTD-GRN and ALS patients

Neuronal Ceroid Lipofuscinosis (NCL)

Homozygous GRN mutations cause NCL:

More severe progranulin deficiency
Potential for protein/gene therapy
Research stage

Other Indications

Alzheimer's disease: Progranulin may have protective effects; being investigated
Parkinson's disease: GRN variants associated with PD risk; therapeutic potential unclear
Psychiatric disorders: Progranulin implicated in depression and schizophrenia

Challenges and Considerations

Delivery Challenges

Blood-brain barrier: CNS delivery remains the primary challenge
Vector distribution: Achieving uniform brain coverage with AAV
Dosing: Determining optimal therapeutic window

Safety Considerations

Immune response: Pre-existing antibodies to AAV vectors
Off-target effects: Potential for overexpression-related toxicity
Long-term expression: Durability and safety over years

Biomarker Development

Need for validated CNS biomarkers: Beyond plasma progranulin
Disease progression markers: For clinical trial endpoints
Patient stratification: Identifying optimal responders

Cross-Links

[GRN Gene](/genes/grn) - Progranulin gene
[Progranulin Protein](/proteins/progranulin) - Protein product
[TDP-43 Protein](/proteins/tdp-43) - Related proteinopathy

[Frontotemporal Dementia](/diseases/frontotemporal-dementia) - Primary indication
[Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis) - Related condition
[Corticobasal Syndrome](/diseases/corticobasal-syndrome) - Related phenotype
[Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy) - Related phenotype

[TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy) - Pathological mechanism
[Lysosomal Dysfunction](/mechanisms/lysosomal-dysfunction) - Therapeutic target
[Neuroinflammation Mechanism](/mechanisms/neuroinflammation-mechanisms) - Related pathway

[Gene Therapy for Neurodegeneration](/therapeutics/gene-editing-neurodegeneration)
[AAV CNS Gene Therapy](/therapeutics/aav-cns-gene-therapy)
[TREM2 Agonists](/therapeutics/trem2-agonists) - Similar approach

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[Baker et al., Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17 (2006) (2006)](https://doi.org/10.1038/nature05017)

[Cruts et al., Null mutations in progranulin cause frontotemporal dementia (2006) (2006)](https://doi.org/10.1038/nature05016)

[Kelley et al., Progranulin deficiency promotes neuroinflammation and neuronal loss (2020) (2020)](https://doi.org/10.1126/science.aax9398)

[Ward et al., Progranulin: A new gene for frontotemporal dementia (2007) (2007)](https://doi.org/10.1007/s00401-007-0205-x)

[Ghidoni et al., The mysterious world of progranulin in neurodegeneration (2008) (2008)](https://doi.org/10.1007/s00401-008-0439-2)

Unknown, PBFT02 Clinical Trial - Phase 1b Study (NCT04885114) (n.d.)

Unknown, AVB-101 Clinical Trial - Phase 1/2 Study (NCT06064890) (n.d.)

Unknown, FRM-0334 Clinical Trial - Phase 1 Study (NCT02472587) (n.d.)

Unknown, DNL593 Clinical Trial - Phase 1/2 Study (NCT05725190) (n.d.)

Unknown, LY3884963 Clinical Trial - Phase 1/2 Study (NCT05549648) (n.d.)

Unknown, VES001 Clinical Trial Program - Multiple Studies (n.d.)

[Ahmed et al., Progranulin: A therapeutic target in frontotemporal dementia (2010) (2010)](https://doi.org/10.1016/j.neurobiolaging.2009.05.005)

[Feng et al., AAV-mediated progranulin delivery rescues neurodegeneration in Grn-deficient mice (2020) (2020)](https://doi.org/10.1093/brain/awaa045)

[Capell et al., Strategies for the treatment of progranulin-deficient frontotemporal dementia (2011) (2011)](https://doi.org/10.1186/alzrt91)

[Chang et al., Progranulin in neurodegenerative disease (2014) (2014)](https://doi.org/10.1016/j.tins.2014.02.007)

[Evers et al., Gene therapy for progranulin-deficient frontotemporal dementia (2017) (2017)](https://doi.org/10.1038/nm.4390)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — 0.44 · Target: TH, AADC
[TREM2-mediated microglial tau clearance enhancement](/hypothesis/h-b234254c) — 0.55 · Target: TREM2
[TREM2 Conformational Stabilizers for Synaptic Discrimination](/hypothesis/h-044ee057) — 0.58 · Target: TREM2
[CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — 0.79 · Target: CYP46A1
[Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — 0.77 · Target: SST
[Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — 0.77 · Target: SMPD1
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Ganglioside Rebalancing Therapy](/hypothesis/h-12599989) — 0.71 · Target: ST3GAL2/ST8SIA1

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) 🔄
[TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
[Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) 🔄
[Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) 🔄

📖 View canonical wiki page →

Progranulin Therapy

Progranulin Therapy

Overview

Progranulin Therapy

Overview

Mechanism of Action

Progranulin Deficiency in Disease

Therapeutic Target

Therapeutic Strategies

1. Gene Therapy (AAV-Mediated)

2. Protein Replacement Therapy

3. Small Molecule Progranulin Boosters

4. Antisense Oligonucleotides (ASOs)

5. Cell-Based Therapy

Clinical Development Status

Active Clinical Trials

Clinical Trial Summary

Biomarkers for Clinical Trials

Progranulin Level Monitoring

Disease Progression Markers

Trial Design Considerations

Preclinical Evidence

Animal Models

Key Preclinical Findings

Therapeutic Applications

Frontotemporal Dementia (FTD-GRN)

Amyotrophic Lateral Sclerosis (ALS)

Neuronal Ceroid Lipofuscinosis (NCL)

Other Indications

Challenges and Considerations

Delivery Challenges

Safety Considerations

Biomarker Development

Cross-Links

Related Gene/Protein Pages

Related Disease Pages

Related Mechanism Pages

Related Treatment Pages

See Also

External Links

References

Related Hypotheses